TORONTO, Aug. 28, 2018 /PRNewswire/ - (CSE: PBT.U) (OTC: PTGEF) Portage Biotech Inc. ("Portage" or the "Company") wishesto announce that, further to its news release of August 14, 2018 announcing the proposed acquisition of SalvaRx Limited from SalvaRx Group plc, it has now submitted draft shareholder meeting materials to CSE for review.
Neither CSE nor its Market Regulator (as the term is defined in the policies of CSE) accepts responsibility for the adequacy or accuracy of this release.
This news release may contain forward looking statements concerning future operations of Portage Biotech Inc. (the "Company"). All forward looking statements concerning the Company's future plans and operations, including management's assessment of the Company's expectations or beliefs may be subject to certain assumptions, risks and uncertainties beyond the Company's control. Investors are cautioned that any such statements are not guarantees of future performance and that actual performance and financial results may differ materially from any estimates and projections.
View original content:http://www.prnewswire.com/news-releases/portage-provides-update-on-proposed-acquisition-of-salvarx-300703387.html
SOURCE Portage Biotech Inc.
Subscribe to our Free Newsletters!
Pneumonitis usually refers to inflammation of lung tissue due to various non-infective causes such ...
Fremanezumab-vfrm is used as a preventive treatment for a migraine headache in adult patients. It ...
DOOR syndrome is a rare genetic disorder marked by deafness, short or absent fingernails, abnormal ...View All